Table 3.

Treatment-related adverse events reported in two or more patients during Stage 2

TRAE, n	Navoximod 200 mg + Atezolizumab (N = 3)	Navoximod 400 mg + Atezolizumab (N = 3)	Navoximod 600 mg + Atezolizumab (N = 3)	Navoximod 1000 mg + Atezolizumab (N = 1)	Total (N = 10)
Any
All grades	3	3	3	1	10
Grade ≥ 3	1	2	0	0	3
Fatigue
All grades	1	0	1	0	2
Grade ≥ 3	0	0	0	0	0
Chromaturia
All grades	2	0	3	1	6
Grade ≥ 3	0	0	0	0	0
Decreased appetite
All grades	1	1	1	0	3
Grade ≥ 3	0	0	0	0	0
Hyponatraemia
All grades	1	1	0	0	2
Grade ≥ 3	1	1	0	0	2
AST increased
All grades	0	2	0	0	2
Grade ≥ 3	0	1	0	0	1
ALT increased
All grades	0	2	0	0	2
Grade ≥ 3	0	1	0	0	1

ALT alanine aminotransferase, AST aspartate aminotransferase, TRAE treatment-related adverse event